Poongjeon Pharmacy to conduct ₩3B third-party allotment rights offering
Predicted impact: Medium
₩3B third-party rights offering is about 14% of market value, well above 5% threshold.
Poongjeon Pharmacy풍전약품
298060 · KOSDAQ · ₩298060 · 풍전약품
₩2,370▲ ₩140 (6.28%)End-of-day · Oct 28, 2026 · End-of-day prices.
Price · 1Y −58.16%
- Market cap
- ₩23B
- Enterprise value
- ₩16B
- P/E
- —
- P/B
- 0.7×
- Dividend yield
- 0.0%
- ROE
- −17.6%
- Net margin
- −19.2%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−62.7% from the high
₩2,125Today: ₩2,230 – ₩2,375₩6,350
Returns
- 1W+7.7%
- 1M−0.2%
- 3M−4.8%
- 6M−48.9%
- YTD−53.2%
- 1Y−58.2%
- Volume today
- 18,731
- 3.9× the 20-day average
- Traded today
- ₩43M
- Listed shares
- 9,637,447
- EPS (12 months)
- −₩590
- Earnings yield −24.9%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Why is it moving?
+6.3% on Oct 28, 2026. Trading value 4.0× its normal.
Poongjeon Pharmacy has announced a 3 billion won third-party share offering, meaning new shares are being sold to selected outside buyers to raise money. A regulatory filing was also made on the same day describing the decision. The sources do not say how the money will be used or how the share price will be affected.
AI summary of the news and filings linked. It can be wrong; check them.
- • Foreign investors bought a net ₩504,645 that day
- • Buzz 63 on JONBUR: heavy trading
Possible reasons, not certainties. Not financial advice.
Signals
Warming up- BuzzRisingBuzz 63: heavy trading.
- SentimentNegativeNews: A new share sale to raise cash can dilute existing shareholders, so the news leans slightly negative. Community: 0 bullish, 0 bearish posts this week.
- MomentumFlat-2.9% over the last month; the price is above its 20-day average.
- News impactSome2 news items and filings in two weeks; 0 rated high impact, 2 medium.
Signals describe activity, not recommendations. Not financial advice.
Poongjeon Pharmacy stock overview
Poongjeon Pharmacy (풍전약품, KRX: 298060) is listed on KOSDAQ, in the Biotech & Pharma sector. SCM Lifescience develops stem cell therapies using its proprietary layer-separation culture method for rare and immune-related diseases, including chronic graft-versus-host disease, acute pancreatitis, and atopic dermatitis. Its shares closed at ₩2,370 on Oct 28, 2026, up 6.28% on the day, giving it a market value of ₩23B.
Key facts
- Market cap
- ₩23B
- Sector
- Biotech & Pharma
- Latest price change
- +6.28%
- As of
- Oct 28, 2026
- Main business
- SCM Lifescience develops stem cell therapies using its proprietary layer-separation culture method for rare and immune-related diseases, including chronic graft-versus-host disease, acute pancreatitis, and atopic dermatitis.
Quick answers about Poongjeon Pharmacy
- What does Poongjeon Pharmacy do?
- SCM Lifescience develops stem cell therapies using its proprietary layer-separation culture method for rare and immune-related diseases, including chronic graft-versus-host disease, acute pancreatitis, and atopic dermatitis. It also sells hair and skin care products under its iroro and DERMASSIMO brands, some exported to Southeast Asia and Japan, and plans to add a pharmaceutical wholesale business in April 2026.
- What is the market cap of Poongjeon Pharmacy?
- The market capitalisation of Poongjeon Pharmacy was ₩23B at the close on Oct 28, 2026.
- Who are the largest shareholders of Poongjeon Pharmacy?
- According to the latest official filings, the largest reported holders are Marcia New Technology Partnership No. 77 (47.98%, as of Jul 6, 2026); Cony New Technology Investment Partnership No. 63 (16.48%, as of Jul 6, 2026); Aria New Technology Partnership No. 95 (10.71%, as of May 4, 2026).
- When is the next earnings report from Poongjeon Pharmacy?
- Korean companies rarely announce results dates in advance. Based on when Poongjeon Pharmacy filed the same report in past years, its next 3q results is expected between Oct 31, 2026 and Nov 14, 2026.
Company profile
SCM Lifescience develops stem cell therapies using its proprietary layer-separation culture method for rare and immune-related diseases, including chronic graft-versus-host disease, acute pancreatitis, and atopic dermatitis. It also sells hair and skin care products under its iroro and DERMASSIMO brands, some exported to Southeast Asia and Japan, and plans to add a pharmaceutical wholesale business in April 2026.
Written by AI from the company's latest annual report.
- Korean name
- 풍전약품
- Sector
- Biotech & Pharma
- Themes
- Pharmaceuticals
- CEO
- 김유정
- Founded
- Jul 2014
- Listed
- Jun 2020
- Listed shares
- 9,637,447
- Fiscal year ends
- Month 12
- Website
- www.scmlifescience.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,372,000−0.15%
- Celltrion068270 · ₩44T₩189,800+0.64%
- Alteogen196170 · ₩16T₩223,000+2.06%
- SK biopharmaceuticals326030 · ₩5.9T₩75,200+0.40%
- Yuhan000100 · ₩5.7T₩77,300−3.38%
- HLB028300 · ₩5.4T₩40,650+1.88%
- Hanmi Pharm128940 · ₩4.7T₩369,500+5.42%
- SAM Chun Dang Pharm000250 · ₩4.5T₩190,000+1.28%
Recent news
Recent filings
See all- Rights offering (paid-in capital increase) decisionOct 26, 2026
- Results of Extraordinary Shareholders' MeetingSep 30, 2026
- 5%+ holding reportSep 30, 2026
- Amended: Shareholders' meeting calledSep 15, 2026
- Notice of shareholders' meetingSep 15, 2026
Titles in Korean until English translations are added.
Also known as: Poongjeon Pharmacy / 풍전약품 / 298060 / KRX:298060
Source: KRX statistical information